CALGB 140803—Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238 No significant financial relationships to disclose ...

Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) ...

In patients with small, peripheral non–small cell lung cancer (NSCLC), visceral pleural invasion leads to worse disease-free and recurrence-free survival as well as higher rates of recurrence, ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Among patients with well-differentiated metastatic thyroid carcinoma, mortality risk factors include ...

Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease ...

The median survival of patients undergoing trimodality therapy is 1–2 years, but some patients (19%) can live for 3–14 years. To improve outcomes and survival, the focus of clinical research over the ...

The addition of chemoradiation therapy to cytoreductive surgery for malignant pleural mesothelioma can improve survival. 1 Postradiation sarcoma has been reported in patients with breast, cervical, ...

The pleural space is defined by the visceral pleura, which covers the lung, and the parietal pleura, which covers the chest wall, diaphragm, and mediastinum. It is estimated that pleural effusion ...